These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 26818640)

  • 1. Botulinum toxin as a treatment for refractory overactive bladder.
    Harris S; Rizzolo D
    JAAPA; 2016 Feb; 29(2):1-4. PubMed ID: 26818640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urodynamic assessment of children treated with botulinum toxin A injections for urge incontinence: a pilot study.
    Lahdes-Vasama TT; Anttila A; Wahl E; Taskinen S
    Scand J Urol Nephrol; 2011 Dec; 45(6):397-400. PubMed ID: 21740110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of botulinum toxin-A in refractory idiopathic overactive bladder patients without detrusor overactivity.
    Kanagarajah P; Ayyathurai R; Caruso DJ; Gomez C; Gousse AE
    Int Urol Nephrol; 2012 Feb; 44(1):91-7. PubMed ID: 21643644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objective and subjective improvement in children with idiopathic detrusor overactivity after intravesical botulinum toxin injection: A preliminary report.
    Al Edwan GM; Mansi HH; Atta ONM; Shaath MM; Al Adwan R; Mahafza W; Afram KM; Ababneh O; Al Adwan D; Muheilan MM
    J Pediatr Surg; 2019 Mar; 54(3):595-599. PubMed ID: 29887168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin a versus placebo for refractory detrusor overactivity in women: a randomised blinded placebo-controlled trial of 240 women (the RELAX study).
    Tincello DG; Kenyon S; Abrams KR; Mayne C; Toozs-Hobson P; Taylor D; Slack M
    Eur Urol; 2012 Sep; 62(3):507-14. PubMed ID: 22236796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of onabotulinumtoxinA injection in patients with refractory overactive bladder: First multicentric study in Turkish population.
    Onem K; Bayrak O; Demirtas A; Coskun B; Dincer M; Kocak I; Onur R;
    Neurourol Urodyn; 2018 Jan; 37(1):263-268. PubMed ID: 28407394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin-A injections for idiopathic overactive bladder: a systematic review and meta-analysis.
    Cui Y; Wang L; Liu L; Zeng F; Niu J; Qi L; Chen H
    Urol Int; 2013; 91(4):429-38. PubMed ID: 23970316
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduction of urgency severity is associated with long-term therapeutic effect after intravesical onabotulinumtoxin A injection for idiopathic detrusor overactivity.
    Kuo HC
    Neurourol Urodyn; 2011 Nov; 30(8):1497-502. PubMed ID: 21717501
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks.
    Khan S; Panicker J; Roosen A; Gonzales G; Elneil S; Dasgupta P; Fowler CJ; Kessler TM
    Eur Urol; 2010 May; 57(5):891-6. PubMed ID: 19394133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of botulinum toxin type A in the single and repeated treatment of overactive bladder. A prospective analysis].
    Frohme C; Varga Z; Olbert P; Schrader AJ; Hofmann R; Hegele A
    Urologe A; 2010 May; 49(5):639-44. PubMed ID: 20182692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Videourodynamic changes of botulinum toxin A in patients with neurogenic bladder dysfunction (NBD) and idiopathic detrusor overactivity (IDO) refractory to drug treatment.
    Alloussi SH; Lang Ch; Eichel R; Al-Kaabneh A; Seibold J; Schwentner C; Alloussi S
    World J Urol; 2012 Jun; 30(3):367-73. PubMed ID: 21842216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates.
    Dowson C; Watkins J; Khan MS; Dasgupta P; Sahai A
    Eur Urol; 2012 Apr; 61(4):834-9. PubMed ID: 22204745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity.
    Kuo HC
    J Urol; 2007 Oct; 178(4 Pt 1):1359-63. PubMed ID: 17706718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [INJECTION OF BOTULINUM TOXIN TYPE A IN THE BLADDER DETRUSOR AND SUBMUCOSA IN PATIENTS WITH OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY].
    Krivoborodov GG; Tur EI; Efremov NS
    Urologiia; 2015; (2):31-4. PubMed ID: 26237802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Intra-detrusor injection of botulinum toxin for female refractory idiopathic overactive bladder syndrome].
    Deffieux X; Fatton B; Denys P; Chartier-Kastler E; Amarenco G; Haab F; Costa P; Game X; Karsenty G; Saussine C; Ballanger P; Le Normand L; Ruffion A; Hermieu JF; Cosson M
    J Gynecol Obstet Biol Reprod (Paris); 2014 Oct; 43(8):572-80. PubMed ID: 25087018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection.
    Khan S; Kessler TM; Apostolidis A; Kalsi V; Panicker J; Roosen A; Gonzales G; Haslam C; Elneil S; Fowler CJ; Dasgupta P
    J Urol; 2009 Apr; 181(4):1773-8. PubMed ID: 19233414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin injections in the management of non-neurogenic overactive bladders in children.
    Léon P; Jolly C; Binet A; Fiquet C; Vilette C; Lefebvre F; Bouché-Pillon-Persyn MA; Poli-Mérol ML
    J Pediatr Surg; 2014 Sep; 49(9):1424-8. PubMed ID: 25148752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In the human urothelium and suburothelium, intradetrusor botulinum neurotoxin type A does not induce apoptosis: preliminary results.
    Kessler TM; Khan S; Panicker JN; Elneil S; Brandner S; Fowler CJ; Roosen A
    Eur Urol; 2010 May; 57(5):879-83. PubMed ID: 19765885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Urodynamic Results of Repeated Intradetrusor Onabotulinum Toxin A Injections in Refractory Neurogenic Detrusor Overactivity: Up to 5 Injections in a Cohort of Children With Myelodysplasia.
    Sekerci CA; Tanidir Y; Garayev A; Akbal C; Tarcan T; Simsek F
    Urology; 2018 Jan; 111():168-175. PubMed ID: 28943369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.